MedTrace Logo

Effectiveness of Higher Aspirin Dosing for Prevention of Preeclampsia in High Risk Obese Gravida

NCT03961360 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 220

Last updated 2024-05-08

Study results available
· View outcomes & findings →

Summary

To compare the incidence of preeclampsia in obese pregnant women (BMI greater than 30) with a singleton gestation at less than 20 weeks and either a history of preeclampsia in a prior pregnancy or stage I hypertension or pre-gestational diabetes who are randomized to either 81mg/day aspirin or 162mg/day aspirin.

Conditions

  • Pre-Eclampsia
  • Hypertension in Pregnancy
  • Obesity

Interventions

DRUG

Aspirin 81 mg

Low dose aspirin was initially reported as having a beneficial effect at preeclampsia

DRUG

Aspirin 162 mg

Low dose aspirin was initially reported as having a beneficial effect at preeclampsia

Sponsors & Collaborators

  • The University of Texas Health Science Center, Houston

    lead OTHER

Principal Investigators

  • farah Amro, MD · University of Texas Health Science Center of Houston

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-05-06
Primary Completion
2023-04-10
Completion
2023-04-10
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03961360 on ClinicalTrials.gov